These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24781039)

  • 21. Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial.
    Vilar L; Fleseriu M; Naves LA; Albuquerque JL; Gadelha PS; dos Santos Faria M; Nascimento GC; Montenegro RM; Montenegro RM
    Endocrine; 2014 Aug; 46(3):577-84. PubMed ID: 24272601
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.
    Colao A; Bronstein MD; Freda P; Gu F; Shen CC; Gadelha M; Fleseriu M; van der Lely AJ; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Sheppard M;
    J Clin Endocrinol Metab; 2014 Mar; 99(3):791-9. PubMed ID: 24423324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral estroprogestin: an alternative low cost therapy for women with postoperative persistent acromegaly?
    Vallette S; Serri O
    Pituitary; 2010 Dec; 13(4):311-4. PubMed ID: 20535640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study.
    Grottoli S; Celleno R; Gasco V; Pivonello R; Caramella D; Barreca A; Ragazzoni F; Pigliaru F; Alberti D; Ferrara R; Angeletti G
    J Endocrinol Invest; 2005 Dec; 28(11):978-83. PubMed ID: 16483175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.
    Chin SO; Chung CH; Chung YS; Kim BJ; Kim HY; Kim IJ; Kim JG; Kim MS; Kim SY; Lee EJ; Lee KY; Kim SW
    BMJ Open; 2015 Jun; 5(6):e006898. PubMed ID: 26063564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical and quality of life responses to octreotide-LAR in acromegaly.
    Mangupli R; Camperos P; Webb SM
    Pituitary; 2014 Dec; 17(6):495-9. PubMed ID: 24178448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study.
    Colao A; Cappabianca P; Caron P; De Menis E; Farrall AJ; Gadelha MR; Hmissi A; Rees A; Reincke M; Safari M; T'Sjoen G; Bouterfa H; Cuneo RC
    Clin Endocrinol (Oxf); 2009 May; 70(5):757-68. PubMed ID: 19178516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-Term Remission of Acromegaly after Octreotide Withdrawal Is an Uncommon and Frequently Unsustainable Event.
    Casagrande A; Bronstein MD; Jallad RS; Moraes AB; Elias PC; Castro M; Czepielewski MA; Boschi A; Ribeiro-Oliveira A; Schweizer JR; Vilar L; Nazato DM; Gadelha MR; Abucham J;
    Neuroendocrinology; 2017; 104(3):273-279. PubMed ID: 27161443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Surgical debulking of pituitary adenomas improves responsiveness to octreotide lar in the treatment of acromegaly.
    Fahlbusch R; Kleinberg D; Biller B; Bonert V; Buchfelder M; Cappabianca P; Carmichael J; Chandler W; Colao A; George A; Klibanski A; Knopp E; Kreutzer J; Kundurti N; Lesser M; Mamelak A; Pivonello R; Post K; Swearingen B; Vance ML; Barkan A
    Pituitary; 2017 Dec; 20(6):668-675. PubMed ID: 28825168
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-acting octreotide LAR compared with lanreotide SR in the treatment of acromegaly.
    Kendall-Taylor P; Miller M; Gebbie J; Turner S; al-Maskari M
    Pituitary; 2000 Oct; 3(2):61-5. PubMed ID: 11141697
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly.
    Chieffo C; Cook D; Xiang Q; Frohman LA
    J Clin Endocrinol Metab; 2013 Oct; 98(10):4047-54. PubMed ID: 23969184
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum markers of cardiovascular risk in patients with acromegaly before and after six months of treatment with octreotide LAR.
    Potter BJ; Beauregard C; Serri O
    Pituitary; 2008; 11(1):49-53. PubMed ID: 17917813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of the efficacy of Octreotide LAR in the treatment of acromegaly--a yearly observation].
    Bałdys-Waligórska A; Gołkowski F; Krzentowska A; Sokołowski G; Hubalewska-Dydejczyk A
    Przegl Lek; 2009; 66(5):218-21. PubMed ID: 19739577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
    Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
    Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?
    Cozzi R; Attanasio R; Montini M; Pagani G; Lasio G; Lodrini S; Barausse M; Albizzi M; Dallabonzana D; Pedroncelli AM
    J Clin Endocrinol Metab; 2003 Jul; 88(7):3090-8. PubMed ID: 12843148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term therapy with long-acting octreotide (Sandostatin-LAR) for the management of acromegaly.
    Davies PH; Stewart SE; Lancranjan L; Sheppard MC; Stewart PM
    Clin Endocrinol (Oxf); 1998 Mar; 48(3):311-6. PubMed ID: 9578821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
    Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.